It specializes in pain management, and its top priority is to continue to identify and develop pain treatments, and to educate the healthcare community about responsible pain management.
In September 2015, the Connecticut-based firm acquired VM-902A from VM Pharma for the potential treatment of chronic pain.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze